Spotlight on Bupropion in Major Depressive Disorder

被引：0
|
作者：
Sohita Dhillon
Lily P. H. Yang
Monique P. Curran
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
CNS Drugs | 2008年 / 22卷
关键词：
Major Depressive Disorder; Sustained Release; Bupropion; Major Depressive Disorder; Escitalopram;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Bupropion is presumed to be a dopamine-noradrenaline (norepinephrine) reuptake inhibitor and is an effective antidepressant. It is available as three oral formulations: (i) bupropion immediate release (IR) [Wellbutrin®] administered three times daily; (ii) bupropion sustained release (SR) [Wellbutrin SR®] administered twice daily; and (iii) bupropion extended/modified release (XR) [Wellbutrin XL®/Wellbutrin XR®] administered once daily. All three formulations are bioequivalent in terms of systemic exposure to bupropion.
引用
收藏
页码：613 / 617
页数：4
相关论文
共 50 条
  • [31] Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder
    Tafseer, Sana
    Gupta, Rachna
    Ahmad, Rafat
    Jain, Seema
    Bhatia, M. S.
    Gupta, Lalit K.
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2021, 200
  • [32] Comparison of aripiprazole augmentation versus bupropion combination for patient with major depressive disorder
    Lee, K.
    Lee, J. B.
    Park, Y. W.
    Lee, J. H.
    Lee, S. J.
    Koo, B. H.
    Sung, H. M.
    Cheon, E. J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S452 - S453
  • [33] Bupropion in the treatment of problematic online game play in patients with major depressive disorder
    Han, Doug Hyun
    Renshaw, Perry F.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2012, 26 (05) : 689 - 696
  • [34] The tolerability and safety of bupropion XL versus escitaloprani in the treatment of major depressive disorder
    Horrigan, J
    Wightman, D
    Modell, J
    [J]. EUROPEAN PSYCHIATRY, 2005, 20 : S144 - S145
  • [35] Probable Bupropion-Related QTc Prolongation in an Adolescent With Major Depressive Disorder
    Naguy, Ahmed
    Alamiri, Bibi
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (01) : E124 - E126
  • [36] Effect of bupropion for nicotine dependece in patients with major depressive disorder: an open clinical trial
    Kim, H.
    Lee, K. J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S549 - S550
  • [37] Agomelatine versus desvenlafaxine versus bupropion XR in the treatment of anhedonia in major depressive disorder
    Romero Guillena, S. L.
    Plasencia Garcia de Diego, B. O.
    Mata Saenz, B. O.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S461 - S462
  • [38] Effect of bupropion for nicotine dependece in patients with major depressive disorder: an open clinical trial
    Kim, H.
    Lee, K. J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S375 - S376
  • [39] Antidepressant for major depressive disorder. Comparison with vortioxetine, agomelatine, desvenlafaxine and bupropion XR
    Plasencia Garcia de Diego, B. O.
    Romero Guillena, S. L.
    Navarro Pablo, R.
    Gotor Sanchez-Luengo, F.
    Santamaria Gomez, O.
    [J]. EUROPEAN PSYCHIATRY, 2018, 48 : S205 - S206
  • [40] DOUBLE-BLIND COMPARISON OF DOXEPIN VERSUS BUPROPION IN OUTPATIENTS WITH A MAJOR DEPRESSIVE DISORDER
    FEIGHNER, J
    HENDRICKSON, G
    MILLER, L
    STERN, W
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1986, 6 (01) : 27 - 32
12345